![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)
[Treatment of hyperuricemia in CKD]
Insights
Hyperuricemia increases kidney disease risk and progression. Xanthine oxidase inhibitors (XOI) show promise for managing hyperuricemia in chronic kidney disease (CKD) patients, but require careful consideration of renal function and toxicity.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hyperuricemia is linked to increased risk of renal failure and cardiovascular events.
- In chronic kidney disease (CKD) patients, hyperuricemia correlates with faster disease progression, mortality, and cardiovascular risks.
- The causal role of hyperuricemia in cardiovascular and renal damage is not fully established, leading to varied treatment approaches.
Purpose of the Study:
- To conduct an evidence-based appraisal of xanthine oxidase inhibitors (XOI) for treating hyperuricemia in CKD patients.
- To evaluate the impact of XOI treatment on the onset and progression of CKD.
- To analyze the toxicity of XOI in patients with varying degrees of renal impairment.
Main Methods:
- Comparative analysis of prospective studies on XOI treatment in CKD.
- Assessment of XOI impact on CKD onset and progression.
- Review of XOI toxicity data across different renal function levels.
Main Results:
- XOI treatment efficacy in managing hyperuricemia and its impact on CKD progression requires further clarification.
- Toxicity profiles of XOI vary with renal function, necessitating dose adjustments.
- Evidence supports careful consideration of XOI for specific CKD patient subgroups.
Conclusions:
- An evidence-based algorithm is proposed to guide clinical decisions on hyperuricemia treatment in CKD patients.
- XOI treatment for hyperuricemia in CKD requires individualized assessment of risks and benefits.
- Further research is needed to fully establish the causal role of hyperuricemia and optimize XOI therapy in CKD.
Abstract:
Numerous epidemiological studies conducted in the general population indicate that hyperuricemia is associated with an increased risk of developing renal failure. Moreover, among those subjects who are already suffering from chronic kidney disease (CKD), hyperuricemia is associated with a more rapid progression of disease besides with an increased risk of mortality and cardiovascular events. However, to date, the causal role of hyperuricaemia in determining the onset and progression of cardiovascular and renal damage is not yet fully established. Therefore the indications for pharmacological treatment of hyperuricemia (and particulary of asymptomatic hyperuricemia) in patients with CKD are still assigned to the personal orientation of the physician. In order to produce an evidence-based clinical appraisal on this topic, we performed a comparative analysis that included all the prospective studies that have evaluated the impact of treatment with xanthine oxidase inhibithors (XOI) with respect to the onset and progression of CKD. Moreover, since in the past the treatment with XOI was associated with a high risk of toxicity in patients with impaired renal function, we analyzed the toxicity of these drugs for various degrees of renal function impairment summarizing indications, contraindications and recommended doses in patients affected by CKD. In the end, as conclusion of our analysis, we propose an algorithm aimed at guiding the clinical decisions about the treatment of hyperuricemia in patients with CKD.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:30Urinary Tract Calculi III: Medical Management
01:27Urinary Tract Calculi IV: Nutrition Therapy and Prevention
01:20Acute Kidney Injury V: Interprofessional Care
01:18Chronic Kidney Disease IV: Nursing Management
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant